Moss NG, Riguera DA, Fellner RC, Cazzolla C, Goy MF. Natriuretic and antikaliuretic effects of uroguanylin and prouroguanylin in the rat. Am J Physiol Renal Physiol 299: F1433-F1442, 2010. First published September 22, 2010 doi:10.1152/ajprenal.00281.2010.-The peptide uroguanylin (Ugn) is stored and released as a propeptide (proUgn) by enterochromaffin cells in the intestine, and converted to Ugn and other metabolites in the renal tubules. Both proUgn and Ugn are natriuretic, although the response to proUgn is thought to depend on its conversion to Ugn within nephrons. To assess the efficiency of intrarenal conversion of proUgn to Ugn, we measured urinary Ugn excretion in rats following intravenous infusions of proUgn or Ugn. Infusion of 2 and 10 nmol proUgn/kg body wt increased plasma proUgn concentration from 2.2 Ϯ 0.3 to 5.6 Ϯ 1.3 pmol/ml and to 37 Ϯ 9.6 pmol/ml, respectively. No proUgn was detected in urine before, during, or after proUgn infusions. These two proUgn infusion doses resulted in total Ugn recovery in urine of 162 Ϯ 64 and 206 Ϯ 39 pmol/kg body wt (9 and 2% of the infused amount, respectively). By contrast, the same molar amounts of Ugn resulted in 1,009 Ϯ 477 and 5,352 Ϯ 2,133 pmol/kg body wt of Ugn in urine (recoveries of ϳ50%). Unexpectedly, comparisons of natriuretic dose-response curves for each peptide showed proUgn to be about five times more potent than Ugn, despite the relatively modest amount of Ugn generated from infused proUgn. In addition, both peptides were antikaliuretic at low doses, but in this case Ugn showed greater potency than proUgn. These data do not support Ugn as the primary active principle of proUgn for regulation of renal sodium excretion.
GUANYLIN (GN) AND UROGUANYLIN (Ugn) are structurally related peptides that stimulate secretory activity in the intestine and inhibit sodium reabsorption by the kidneys (4, 5, 8, 12, 13, 19, 24, 30, 36, 37) . Both peptides are produced in the gastrointestinal tract; Ugn primarily by enterochromaffin (EC) cells in the small intestine and Gn by goblet cells in the colon (6, 27, 28, 39, 40) . Even though both peptides are natriuretic in the kidney, several lines of evidence support a role for Ugn, but not Gn, in volume homeostasis and sodium balance (15) (16) (17) 38) . For example, in contrast to Gn, Ugn is excreted in urine (11), where it is present at levels that are proportional to dietary sodium intake (18) . Furthermore, Ugn knockout mice are hypertensive compared with wild-type controls and show an impaired natriuretic response to increased oral salt intake, whereas Gn knockout mice have normal blood pressures and sodium balance (10, 31) . Thus, Ugn has been credited with a regulatory role in sodium balance that is triggered by alterations in dietary salt intake per se, thereby differing from other sodium regulatory systems that respond to the subsequent changes in extracellular volume and arterial pressure (16, 41) .
The circulating Ugn-related peptide released by EC cells is primarily prouroguanylin (proUgn), with Ugn constituting less than 3% of the total amount (36) . Metabolic tracer studies reveal that proUgn is not converted to Ugn within the circulation, even after 60 min of infusion; instead, several metabolites of proUgn, including Ugn, are produced within the kidney and are excreted in urine (41) . One or more of these metabolites, but principally the 15 amino acid form of Ugn (Ugn-15), has been presumed to be the active agent that is responsible for the natriuresis produced by this enterorenal endocrine axis (17, 36, 41) . This is consistent with the activity of this system in the intestine and, accordingly, most previous studies used either opossum or human Ugn to investigate the role of this endocrine system in renal excretory function (1, 5, 13, 14, 19, 36, 37, 45) .
However, the assumption that Ugn-based mechanisms in the kidney are similar to those in the intestine is now in question, both in terms of the receptors responsible and even the active peptides involved. Within the intestine, Ugn inhibits sodium absorption and stimulates chloride secretion by activating a receptor guanylate cyclase (GC-C) (8, 12, 24, 33, 46) . In contrast, GC-C receptors are not required for renal excretory responses to Ugn, which are preserved in the GC-C knockout mouse (5) . Consistent with this, the GC-C knockout mouse also does not share the hypertension or sodium-handling deficits of the Ugn knockout mouse (10) . In addition, an isomer of Ugn (UgnB) that fails to activate GC-C receptors is natriuretic, both in the rat (37) , and in the GC-C knockout mouse (N. Moss, unpublished data). Thus, an alternative receptor to GC-C must be considered as a major contributor to the renal excretory response to Ugn. The role of Ugn itself in the renal response is also unclear, as it has been noted that doses of Ugn-15 required to elicit natriuretic responses in rats and mice exceed reasonable physiological levels (31) . A plausible rationale for the apparent low potency of Ugn-15 is that an alternate metabolite derived from proUgn may be the true mediator of the enterorenal natriuretic pathway. In this case, the renal phenotype of the Ugn knockout mouse would reflect the loss of the alternate metabolite, rather than the loss of Ugn per se.
One previous report showed that human proUgn is natriuretic when infused intravenously in rats (36) . However, the response was not compared with the effects of an equivalent dose of Ugn, so the extent to which it could be attributed to the intrarenal conversion of proUgn to Ugn is not known. The work described here addresses this question by testing whether the natriuretic activity of intravenous rat proUgn is dependent on intratubular formation of Ugn-15. If this is the mechanism for proUgn activity in the kidney, equimolar intravenous infusions of proUgn and Ugn-15 should elicit equivalent natriuretic effects and, if the conversion of proUgn is complete, result in comparable amounts of Ugn in urine. The use of rat proUgn and rat Ugn is also a novel feature of these studies. To our knowledge, renal excretory responses to Ugn and proUgn in the rat have not previously been investigated with peptides native to this species.
MATERIALS AND METHODS
All experiments were performed on Sprague-Dawley rats (average weight 260 Ϯ 5 g) obtained from a commercial supplier (Harlan Laboratories, Dublin, VA). Animals were maintained on a 12:12-h light-dark cycle in an American Association for Accreditation of Laboratory Animal Care-approved facility with continuously available veterinary care and uninterrupted access to water and standard rat chow. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Peptides Used
Rat Ugn for use in intravenous infusion experiments and as a standard in Ugn-binding assays was purchased from commercial suppliers (Anaspec, San Jose, CA and Peptides International, Louisville, KY). The radioligand for binding studies was prepared from N-tyrosyl rat Ugn (Y-Ugn; Bachem, Torrance, CA). Y-Ugn was labeled with 125 I using precoated iodination tubes according to the manufacturer's instructions (Thermo Scientific, Rockford, IL) and then purified by reverse phase HPLC before use. Recombinant rat proUgn (provided by Ironwoods Pharmaceutical) was produced as a His-tagged trxA fusion protein from plasmid pTM203 in an Origami (DE3) bacterial expression system. The fusion protein was purified by immobilized metal ion affinity chromatography, and proUgn was released by cleavage with PreScission protease. Some of this recombinant proUgn was iodinated by the same procedure used for rat Y-Ugn.
Exprimental Protocols
Renal excretory responses to Ugn and proUgn. Rats were anesthetized with pentobarbital sodium (60 mg/kg ip) and prepared for clearance experiments with a PE-240 cannula in the trachea, one PE-50 and two PE-10 cannulas in a jugular vein, a PE-50 cannula in the left femoral artery, and a PE-10 cannula in each ureter. Rats received an initial infusion of isotonic saline amounting to 6% of body weight over 60 min followed by an intravenous infusion of isotonic saline at 10 l·min Ϫ1 ·100 g body wt Ϫ1 for the remainder of the experiment. A portion of the maintenance infusion (10 l/min) was provided through a PE-10 cannula to deliver peptide infusions; the balance was administered via the PE-50 cannula and included FITClabeled inulin (Sigma, St. Louis, MO) at 400 g/ml (i.e., 12 g·min Ϫ1 ·100 g body wt Ϫ1 ). Supplemental anesthetic was provided as required through the second PE-10 intravenous cannula. Blood samples were obtained from the femoral artery cannula, which was otherwise connected to a pressure transducer system for measurement of arterial blood pressure (model 50110, Stoelting Instruments Wood, Dale, IL). Arterial pressure was digitized with an A/D converter (model KUSB 3100, Keithley Instruments, Cleveland, OH) for display and storage on a personal computer running open layers data acquisition software (Dtx_Ez, Data Translation).
Twenty-minute urine collections were started 1 h after the volume expansion period. Three control collections were followed by three collections during 60 min of peptide infusion and five collections in the postinfusion period. Blood samples were collected at the mid point of alternate urine collections. Renal excretory responses to intravenous infusions were determined for Ugn at doses of 2, 10, and 50 nmol/kg and proUgn at doses of 0.4, 2, and 10 nmol/kg. These dose ranges are based on our previous studies, which showed human UgnA and B to be natriuretic at doses between 20 and 50 nmol/kg body wt (37) and human proUgn to be natriuretic at a dose of 10 nmol/kg body wt (36) . The dose was reduced in fivefold decrements to determine a subthreshold dose for each peptide. A separate group of rats received saline vehicle in place of peptide infusions to provide time control data.
Urine volumes were determined by weight. Sodium and potassium concentrations in plasma and urine were measured by flame emission photometry (model 943, Instrumentation Laboratory, Lexington, MA). FITC-labeled inulin concentrations were measured as described in an earlier publication (37) . In brief, plasma and urine samples were transferred to capillary tubes (10-l microcaps, Drummond Scientific, Broomall, PA) and viewed under ϫ20 magnification with an epifluorescence microscope (Axiovert S100TV, Carl Zeiss, Thornwood, NY). FITC-inulin fluorescence intensity was detected with a CCD camera (Orca II, Hamamatsu, Bridgewater, NJ) and analyzed by Metamorph imaging software (v.7.1, Molecular Devices, Sunnyvale, CA). Background fluorescence was measured in bladder urine and in tail vein plasma collected before the start of inulin infusions. Inulin concentrations in plasma and urine were obtained by interpolation in a standard curve prepared from serial dilutions of the maintenance infusion solution.
Ugn excretion in response to intravenous infusions of Ugn and proUgn. Rats were anesthetized with pentobarbital sodium and prepared as described above for clearance experiments, except inulin was not added to the maintenance infusion. Urine was collected in 60-min periods before, during, and after intravenous infusions of proUgn or Ugn, at 2 and 10 nmol/kg body wt. Urine Ugn concentrations were measured in all urine collections, while proUgn concentrations were measured in urine only from rats receiving proUgn infusions. Plasma proUgn was measured before the start of proUgn infusions and at the completion of the 60-min infusion period. Ugn concentrations were not measured in plasma samples for technical reasons.
In a separate series of rats, the renal excretion of 125 I-labeled proUgn was analyzed after intravenous infusion of labeled proUgn alone or together with unlabeled proUgn in amounts of 0.4, 2, and 10 nmol/kg body wt. Collected urine was passed through a C18 reverse phase HPLC column and the eluted fractions were assessed for 125 I content with a gamma counter. In a further group of rats, the stability of proUgn in plasma was studied by an intravenous bolus injection of 125 I -proUgn in rats after ligation of both renal pedicles. Plasma obtained 150 min after the 125 I-proUgn injection was analyzed by HPLC to reveal any proUgn breakdown products.
Measurement of proUgn in Plasma and Urine
ProUgn concentrations in plasma and urine were measured by a quantitative Western blot assay that has been described in an earlier publication (36) . A preextraction procedure, using a Superdex 75 10/300 GL size exclusion column (GE Healthcare, Life Sciences, Piscataway, NJ), was performed on all samples to separate proUgn from high-abundance plasma proteins or urinary proteins that otherwise interfere with electrophoresis. The Superdex column was eluted with 150 mM NaCl plus 10 mM HEPES (pH 7.0) and the pooled proUgn-containing fractions dialyzed against distilled water, using a 1-kDa cutoff dialysis membrane (SpectraPor 6 dialysis membrane, Spectrum Laboratories, Rancho Domingo, CA). Dialyzed samples were dried and redissolved in boiling SDS electrophoresis buffer. Recovery of proUgn at this stage was 20 Ϯ 2% (n ϭ 5), and correction for these sample losses has been included in all calculations. Extracted plasma and urine samples, together with a dilution series of recombinant proUgn standards, were then run on a gradient gel (4 -12% polyacrylamide, Invitrogen, Carlsbad, CA) and electroblotted onto 0.2-m nitrocellulose membrane (Schleicher and Schuell/Whatman, Florham Park, NJ). The membrane was processed by standard procedures using a primary antibody against rat proUgn (Ab 6910 or 6912) and an infrared-emitting secondary antibody (IRDye 800-coupled goat-anti-rabbit, Rockland, Gilbertsville, PA). Quantification was performed with an Odyssey infrared gel-imaging system (LI-COR Biosciences, Lincoln, NE).
Measurement of Ugn in Urine
This assay is a modification of a previously described radioreceptor binding assay (21) . Our assay is based on competitive binding between Ugn and 125 I-labeled Y-Ugn at GC-C receptors in an isolated T84 cell membrane preparation. Concentrations of Ugn in urine samples are calculated from a standard curve generated with rat Ugn (a 50:50 racemic mix of the rat UgnA and UgnB isomers). The assay is highly specific for guanylin family peptides, which are limited to Ugn in urine (11).
To prepare membranes, T-84 cells were cultured on tissue culture plastic in DMEM/F12 supplemented with 10% fetal calf serum and antibiotics. Upon confluence, cells were harvested in ice-cold buffer (50 mM Tris, 10 mM NaCl, 5 mM MgCl, 2.5 mM CaCl 2) and homogenized with a glass tissue grinder (Radnoti, Monrovia, CA) before centrifugation at 100,000 g for 50 min at 4°C. The supernatant was discarded and the pellet was resuspended in Hanks-buffered salt solution (HBSS; Invitrogen, pH 7.4) and centrifuged at 2,000 g for 5 min at 4°C to pellet nuclear material and membrane aggregates. Membranes remaining in the supernatant were assayed for protein concentration by the Bradford method (Bio-Rad, Hercules, CA) and aliquoted for storage at Ϫ80°C in HBSS until time of use.
Before assay, each sample was reduced to dryness (Savant SpeedVac, Thermo Electron, Waltham, MA) and redissolved in 20-l assay buffer (HBSS, 20 mM sodium citrate, 0.75% bovine serum albumin; Sigma; pH 4.75). Samples were incubated for 1 h at 25°C with 20 l of T84 cell membranes (1-10 g protein) and 0.5 nM 125 I-Y-Ugn and then rapidly filtered through Whatman GF/C glass microfiber filters presoaked in distilled water and rinsed twice with 5 ml of ice-cold buffer containing 50 mM Tris·HCl at pH 7.4. Bound radioligand was quantified with a gamma counter (Packard Cobra, PerkinElmer Life and Analytical Sciences, Waltham, MA). Nonspecific binding was determined by incubation of T84 cell membranes with 125 I-Y-Ugn and 10 Ϫ5 M unlabeled Y-Ugn in place of Ugn standards or unknowns. Ugn concentrations were calculated by interpolation in a standard curve prepared from a dilution series of synthetic rat Ugn standards incubated in parallel with unknowns using the standard equation for a single site ligand displacement assay:
where NSB ϭ nonspecific binding (in the presence of saturating competitor) and B max ϭ maximal binding (in the absence of competitor).
Data Analysis
Basal Ugn excretion rates are expressed in femtomoles per minute per 100 g body wt. Urine Ugn concentrations are expressed as picomoles per milliliter, which approximates the concentration of Ugn within terminal nephron segments and may be correlated with biological activity within the nephrons. Net excreted amount of Ugn for each rat was calculated by subtracting Ugn excretion in the control collection period from excreted amounts during the infusion and post infusion collection periods and expressed as picomoles per killigram of body wt.
Glomerular filtration rate (GFR) was calculated as the clearance of FITC-labeled inulin. Sodium and potassium excretion rates are expressed as nanoequivalents per minute (U NaV and UKV, the urine concentration of each multiplied by urine flow) and fractional excretion (FENa and FEK, the U/PNa and U/PK concentration ratios divided by the coincident U/PIn). Net changes in sodium and potassium excretion were estimated by subtracting values from vehicle-treated rats from corresponding values in experimental groups. Absolute renal function values (Urine flow, GFR, U NaV, UKV) were normalized for kidney weight. Results from both kidneys in each collection period were averaged before calculating group means Ϯ SE.
All graphing and statistical testing were performed with the Prism 5.3 graphing and analysis program (Graphpad Software, San Diego, CA). Group comparisons were made with one-way ANOVA using peptide doses as column variables and individual measurements from each clearance period for each rat as row variables. Columns were subdivided into preinfusion, infusion, and postinfusion groups and tested against corresponding values from vehicle-infused rats with Bonferroni's method for multiple comparisons.
RESULTS

Excretion of proUgn in Urine
HPLC analysis of urine following intravenous infusion of 125 I-proUgn shows that intact propeptide was not excreted. Instead, recovered radioactivity was confined to the void volume (Fig. 1, filled symbols, peak B) , demonstrating complete proteolytic destruction of the parent molecule before its excretion in the urine. Conversely, HPLC analysis of plasma obtained from an acutely nephrectomised animal 150 min after an intravenous bolus of 125 I-labeled proUgn reveals that essentially all 125 I was associated with undigested proUgn (Fig. 1,  peak A, open symbols) . Thus, the propeptide remained intact within the circulation over this time interval. The prolonged survival of intact 125 I-proUgn within a nephrectomized animal contrasts with the rapid removal of proUgn in intact animals and is consistent with previous evidence that renal filtration is the primary mechanism for clearance of proUgn from the circulation (41) .
The capacity of the kidney to degrade intratubular proUgn was tested further by infusing tracer amounts of labeled propeptide into normal (nonnephrectomized) animals, accompanied by increasing amounts of unlabeled propeptide (0.4, 2, and 10 nmol/kg body wt). In each case, the HPLC elution profile of the excreted radioactivity in urine was consistent with complete degradation of the labeled precursor (data are not shown but are indistinguishable from the filled symbols in 1) ; thus, the capacity of nephron proteases to cleave proUgn is not saturated at the plasma levels of proUgn generated in our infusion protocols. These data are consistent with a previous study that investigated the metabolic fate of 35 S-met/ 35 S-cys-labeled proUgn (41), but that study also detected several labeled urinary metabolites (eluting in fractions 32, 34, 39, and 43) that were not observed here. Evidently, these previously observed proUgn-derived peptides contain cysteine and/or methionine, but not tyrosine.
Excretion of Ugn in Urine 1: proUgn Infusions
After 60 min of intravenous infusion with nonradioactive rat proUgn at 2 nmol/kg body wt, plasma proUgn concentration increased from 2.2 Ϯ 0.3 (n ϭ 6) to 5.6 Ϯ 1.3 pmol/ml (n ϭ 3, P Ͻ 0.01, unpaired t-test). This is within the normal range for plasma proUgn in rats (36) . Infusion of 10 nmol proUgn/kg body wt increased plasma proUgn to 37 Ϯ 9.6 pmol/ml over the same time period (P Ͻ 0.0001, n ϭ 3, unpaired t-test). This is significantly higher than would be seen in normal rats, but is commonly achieved in rats with renal failure produced by a 5/6 reduction in renal mass (N. Moss, unpublished observation).
In Fig. 2 , Ugn excretion is shown as the concentration of Ugn in urine ( Fig. 2A) , the net increase in Ugn excreted during and after proUgn infusion (Fig. 2B ) and the recovery of Ugn as a percent of proUgn infused (Fig. 2C) . The Ugn concentration provides an index of the intratubular "dose" of Ugn generated from proUgn, while the amount excreted provides a means to assess the efficiency of this conversion process. The increase in urinary Ugn concentration during the 10-nmol/kg proUgn infusion was significantly greater than the increase during the 2-nmol/kg infusion (40.6 Ϯ 5.2 vs. 10.5 Ϯ 1.6 pmol/ml, P Ͻ 0.01), indicating a dose-dependent response for Ugn activity generated from proUgn infusions. The total recovered amount of Ugn in urine (summed over the infusion and postinfusion periods) was 162 Ϯ 64 pmol/kg body wt for 2-nmol proUgn/kg infusions and 206 Ϯ 39 pmol/kg for 10-nmol proUgn/kg infusions (Fig. 2B) , which amounts to 9 and 2% of the infused dose of proUgn, respectively (Fig. 2C ). This contrasts with plasma proUgn levels, which increased by ϳ250 and ϳ1,700% during the 2-and 10-nmol/kg infusion rates, respectively. The extremely low recoveries of Ugn derived from proUgn suggest either that Ugn production within the tubules is relatively inefficient or that Ugn may be produced but is largely degraded and/or reabsorbed before it can be excreted.
Excretion of Ugn in Urine 2: Ugn Infusions
For comparison with the results of propeptide infusions (Fig.  2) , urine Ugn excretion in response to intravenous infusions of rat Ugn itself is shown in Fig. 3 . The concentration of Ugn in urine increased from 7.6 Ϯ 3.5 pmol/ml to a peak of 284 Ϯ 124 pmol/ml following infusion of Ugn at 2 nmol/kg (Fig. 3A, ) , which was almost 8 times higher than the concentration of Ugn produced from the same molar amount of proUgn (37 Ϯ 9.6 pmol/ml; Fig. 2A, ; note the different scales of the y-axes). Urine Ugn increased from 7.5 Ϯ 1.9 pmol/ml to a peak of 820 Ϯ 111 pmol/ml during the 10-nmol/kg infusion (Fig. 3A, ), which is more than 10 times higher than the concentration achieved with intravenous infusions of the same molar amounts of proUgn (Fig. 2A, ) . The amount of Ugn recovered in urine was ϳ1,000 pmol after 2-nmol/kg infusions and ϳ5,000 pmol after 10-nmol/kg infusions (Fig. 3B) , or ϳ50% of the total infused amount in both cases (Fig. 3C) .
The fate of unrecovered Ugn is unknown, but is not due to delayed excretion, as the urine Ugn concentrations returned close to baseline levels in the second hour following the intravenous infusion (Fig. 3A) . It is more likely that several processes reduced the recovery, including degradation within the proximal tubules and removal from the circulation by nonrenal clearance mechanisms. However, the relatively robust recovery of infused Ugn (ϳ50%), compared with the relatively poor recovery of Ugn derived from infused proUgn (ϳ2-9%, see above), argues that Ugn is not produced stoichiometrically from proUgn within the tubule.
In summary, proUgn infusions produce very small increases in urinary Ugn excretion relative to those observed when Ugn itself is infused.
Renal Excretory Responses to Ugn and proUgn
The effects of rat Ugn and proUgn infusions on renal excretory activity are summarized in Table 1 and Figs. 4 and 5. As shown in the table, GFR and arterial pressure were relatively stable throughout the clearance experiments and not different between vehicle-and peptide-infused groups at any time. Pressure fell during the protocol by an average of 7 mmHg for all groups, but this decrease was not statistically significant, and did not differ between groups. Urine flow was significantly increased over the vehicle group during the postinfusion period for the 50-nmol/kg dose of Ugn and during the infusion and postinfusion periods for the 10-nmol/kg doses of proUgn.
The time courses of natriuretic responses (U Na V) to 60-min infusions of rat Ugn and proUgn are shown in Fig. 4, A and B . Both peptides were natriuretic, in agreement with earlier reports in rats using opossum and human Ugn and human proUgn (13, 14, 36, 37, 45) . Both of the rat peptides evoked prolonged responses, lasting well beyond the end of the infusion period, as also noted in earlier reports on the renal actions of human Ugn (37) . The natriuresis was only statistically significant for the highest doses of each peptide used (10 nmol/kg body wt of proUgn and 50 nmol/kg body wt of Ugn), and only in urine produced after the termination of peptide infusions. However, a dose-response relationship is apparent for each peptide. This relationship is left-shifted in proUgninfused animals (Fig. 4C) , with the result that sodium excretion following 10-and 50-nmol/kg infusions of Ugn are equivalent to the 2-and 10-nmol/kg doses of proUgn, respectively. Fractional sodium excretion (FE Na ) followed the same response pattern as U Na V (Table 1) .
Potassium excretory responses (U K V) to the two peptides are summarized in Fig. 5, A and B. Fractional potassium excretion (FE K ) is given in Table 1 . Both peptides were antikaliuretic at the lowest dose tested, and Ugn also produced a significant antikaliuresis at 10 nmol/kg body wt. This is indicative of a "potassium sparing" action for Ugn and proUgn at low doses, which either desensitizes or is overridden by an opposing mechanism at higher doses. One likely possibility is that the antikaliuresis is counteracted at higher doses by the natriuretic and diuretic effects of the peptides that emerge at these doses (Fig. 4, A and B) . Values are means Ϯ SE. ABP, mean arterial blood pressure; GFR, glomerular filtration rate; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; Ugn, uroguanylin; proUgn, prouroguanylin; Ugn-2, -10, and -50, rats infused with 2, 10, or 50 nmol/kg Ugn, respectively; proUgn-0.4, -2, and -10, rats infused with 0.4, 2, and 10 nmol/kg proUgn, respectively; _Pre, _Inf, and _Post, preinfusion, infusion, and postinfusion collection periods. *P Ͻ 0.05, †P Ͻ 0.01 compared with corresponding period in vehicle group by 1-way ANOVA and Bonferroni's multiple range test. N ϭ number of animals per group.
Net potassium excretion is depressed to a greater degree by Ugn than by proUgn at the 2-and 10-nmol/kg doses (Fig. 5C) . Thus, in contrast to their actions on sodium excretion, Ugn appears to be a more potent antikaliuretic agent than proUgn. However, to fully characterize the actions of the two peptides on potassium excretion, additional experiments are required over a greater dosage range than has been explored here.
DISCUSSION
These studies confirm our previous finding of a natriuretic response to proUgn in rats (36) and extend this finding in several important ways. First, proUgn proved to be a fivefold more potent natriuretic factor than Ugn, the currently recognized mature form of the peptide. Second, this differential response was not correlated with urine Ugn concentrations, which were increased 5-to 10-fold by a natriuretic dose of proUgn and 30-to 50-fold by a nonnatriuretic dose of Ugn. Third, an antikaliuretic response was observed for both Ugn and proUgn. This differs from earlier reports that describe kaliuretic effects for these peptides (5, 13, 36) . Finally, the dose-response relationship for proUgn falls within the plasma concentration range seen for native proUgn, confirming the physiological relevance of this relationship. Taken together, these data support a role for proUgn in volume homeostasis, but challenge the notion that Ugn is the active metabolite responsible for this activity.
Intrarenal Conversion of proUgn to Active Metabolites
Intrarenal processing of proUgn to Ugn has been confirmed in this study, but the relatively modest increase in urinary Ugn excretion during proUgn infusions is striking compared with the substantial increases caused by equimolar infusions of Ugn. This cannot be the result of incomplete degradation of proUgn, as the propeptide is completely cleared from the plasma within 60 min after the infusion is terminated (data not shown), and fails to appear in an intact form in urine (Fig. 1) . Furthermore, the ratio of infused proUgn to recovered Ugn in our studies (ϳ100:1) is similar to the ratio between the normal filtered load of native proUgn (between 4 and 5 pmol/min in rats) and the urinary excretion of native Ugn (30 -50 fmol/min in the rats studied here-again ϳ1% of filtered load). The proUgn-to-Ugn conversion process may also be close to saturation, as the increase in urinary Ugn excretion caused by 10-nmol/kg infusions of proUgn was only 25% greater than that seen after the 2-nmol/kg infusion.
These findings make it very improbable that proUgn infusions could ever generate Ugn levels in urine comparable with those seen with Ugn infusions. Despite this, a fivefold higher dose of Ugn is required to match the natriuretic response to proUgn. Thus, the possibility exists that a more effective natriuretic agent than Ugn is generated from proUgn within the renal tubules. Several variants of Ugn have been reported, not all of which have been identified in urine, but could nevertheless be considered potential mediators of solute reabsorption from real tubules. The active form of Ugn in rodents has been identified as a 15-amino acid peptide (Ugn-15) (11, 39), but an 18 amino acid variant has also been described (29, 39) . In humans, Ugn-16 is accepted as the main form (25) , but a 24-amino acid variant is also recognized in human plasma (23) . In the opossum, 13-, 14-, and 15-amino acid peptides have all been identified (22) .
It is important to also consider that all of the previously described "active" fragments of proUgn have been identified through GC-C receptor activation, and it is now clear that this is not required for biological activity of guanylin family peptides in the kidney (5, 37, 47) (Qian X, Moss NG, Fellner RC, Taylor-Blake B, Goy MF, Am J Physiol Renal Physiol). Therefore, peptide fragments that do not activate GC-C receptors, such as the 16-and 94-amino acid sequences of proguanylin (49), will not have been recognized as potential natriuretic factors. This is a very different situation from the intestine, where GC-C receptors are indispensible for the secretory activity of Ugn (33, 46) . Indeed, the differing nature of the receptor populations in gut and kidney raises the possibility that the propeptide might be differentially processed in the two tissues. For example, Medeiros and Turner (35) reported that incubation of neuropeptide Y with jejunal or renal brushborder enzymes generates distinct sets of metabolites with different receptor affinities. The same could apply to proUgn, leading to the generation of active metabolites that are tailored for the specific requirements of renal and intestinal environments. In this regard, radio-labeled tracer studies identified at least one major proUgn metabolite in urine, in addition to Ugn (41) . Screening this and other potential proUgn-derived peptides for biological activity in the kidney will require renal function assays such as those described here.
Effects of Ugn and proUgn on Sodium Excretion
The natriuretic responses to Ugn and proUgn were not associated with increases in GFR and can therefore be attributed to alterations in tubular solute reabsorption. However, a pronounced natriuretic response to both peptides was limited to the highest dose of each (Fig. 3) , which also generated a diuresis (Table 1) . Similar coupled natriuretic and diuretic responses have been observed in previous studies of the renal actions of Ugn (13, 14, 45) , although an earlier report from our own laboratory showed a natriuretic response to human Ugn isomers at doses that did not cause a diuresis (37) . This may represent differences in the renal response to human and rat peptides, which have significant structural differences at the COOH terminus that affect the stability of the peptide (34), but is more likely to have resulted from the hydration state of the rats. Animals were not volume expanded in the earlier study, and therefore showed a lower basal level of urine output and sodium excretion (0.09% of filtered load vs. 0.9% in this study).
The prolonged natriuresis following proUgn or Ugn infusion is quite unlike the rapid onset and reversal of the natriuretic response caused by GC-A receptor activation with ANP or BNP (3, 42) . Rather, the slow, long-latency response to Ugn peptides is consistent with a genomic action that was first described by Carrithers et al. (5) in the mouse. In that study, Ugn infusions caused a downregulation of mRNAs for a renal tubular chloride channel, CLCK2, and a subunit of ATPase (5), both of which are important elements in solute reabsorption from renal tubules (26) . This type of effector pathway is not associated with GC-C receptor activity in the intestine, and implicates an alternative Ugn receptor in the kidney, perhaps the same as that which produces the natriuretic response to Ugn in GC-C knockout mice (5) . Indeed, the similar time courses of the responses evoked by Ugn and proUgn reveal that the two peptides act through comparable "slow" signal transduction mechanisms, and thus, perhaps, through the same alternative receptor.
It has been reported that the natriuretic response to Ugn is sensitized by high levels of sodium intake (14) and by a synergistic relationship between ANP and Ugn at low concentrations (44, 45) . We did not measure ANP in this study, and plasma ANP levels may have increased during the 60-min expansion period that was provided at the start of all clearance protocols. However, direct measurements of plasma peptide levels in response to isotonic volume expansion showed that ANP concentrations revert to basal levels within 15 min after the expansion stimulus (2, 9), with correspondingly transient renal and vascular responses (3, 7, 32, 42 ). In the experiments described here, the peptide infusions were started 120 min after the end of the volume expansion, and so plasma ANP levels are not likely to have been elevated above basal levels. Moreover, residual synergistic effects of ANP (if any) would have been manifested equally in both the Ugn and proUgn infusion studies, and hence could not have been responsible for observed differences between the two peptides.
Effects of Ugn and proUgn on Potassium Excretion
The reduction in potassium excretion observed at lower doses of Ugn and proUgn (Fig. 5) was unexpected, as the majority of previous studies reported a kaliuretic action of Ugn in isolated, perfused rat kidneys and in vivo mouse preparations (4, 5, 13, 19, 30, 36) . However, as mentioned above, these previous studies consistently included a diuresis that will have provided an indirect, flow-dependent stimulus for potassium excretion (20, 43, 48) . In the present study, an antikaliuresis was observed only at lower doses and was progressively reversed at increasing doses that were also associated with enhanced diuresis and natriuresis. Thus, an antikaliuretic effect may have been offset at the highest doses by a separate stimulus for potassium excretion related to flow-dependent mechanisms in the distal tubules.
Sindic et al. (47) reported that Ugn inhibited secretory potassium channels in isolated cortical collecting duct cells, a mechanism that could underlie the antikaliuresis shown in Fig.  5 . As with our results, this is inconsistent with the kaliuretic effect of Ugn reported in intact kidneys, as well as with microperfusion studies that documented elevated potassium secretion in rat distal tubules following a relatively high dose of Ugn (1) . However, such disagreements may reflect differences in the effective doses of peptides that have been delivered in each case, since full dose-response ranges have not typically been explored in most studies. Indeed, our own study has not established the full dose-response range for the antikaliuretic effects of Ugn and proUgn, and this remains an important area for future research.
Perspectives
Why intestinal EC cells should release proUgn rather than Ugn has not been addressed in earlier descriptions of this endocrine system. The present data provide a provocative answer to this question, by revealing a more potent natriuretic response to proUgn than to Ugn in the kidney. Furthermore, the plasma levels of proUgn that elicit this natriuretic response are within measured levels of the native peptide (36) , while doses of Ugn with comparable efficacy result in Ugn concentrations in urine that are many times greater than naturally occurring levels (Fig. 3) . Thus, proximal tubular enzymes may initiate a natriuretic response by generating an active peptide from proUgn that is distinct from Ugn. The data do not preclude a role for Ugn in renal function, but present the possibility that an antikaliuretic action of Ugn may complement the natriuretic action of an alternate metabolite of proUgn. This might help to conserve potassium stores during a natriuretic stimulus, and would provide a comprehensive homeostatic role for proUgn in the maintenance of sodium and potassium balance.
